Products for Research Use Only

NVP-TAE 226

CAT: 0804-HY-13203-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13203-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC50s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC50s of 3.5 nM and 44 nM, respectively[1][2].
CAS Number
761437-28-9
Product Name Alternative
TAE226
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; FAK; IGF-1R; Insulin Receptor; Pyk2
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/NVP-TAE-226.html
Purity
99.77
Solubility
DMSO : 11.11 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=C(C=CC=C1)NC2=NC(NC3=C(C=C(C=C3)N4CCOCC4)OC)=NC=C2Cl)NC
Molecular Formula
C23H25ClN6O3
Molecular Weight
468.94
Precautions
H302, H315, H319, H335
References & Citations
[1]Liu TJ, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther, 2007, 6 (4), 1357-1367.|[2]Delimont D, et al. Laminin α2-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis. PLoS One. 2014 Jun 10;9 (6) :e99083.|[3]Lietha D, et al. Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One. 2008;3 (11) :e3800.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported